Cleerly

?? Team Cleerly is heading to ACC.25 and we can't wait to connect! Join us as we share how our AI-powered plaque analysis is setting a new standard in cardiac care. https://lnkd.in/gtdjSHwr Our busy schedule includes key sessions where Cleerly leadership will discuss AI, cardiovascular disease prevention, and the latest clinical research. Plus, live demos daily at Booth 16033. ?? We're honored to participate in this incredible event and eager to showcase how our advanced AI technology empowers healthcare professionals to make confident, data-driven decisions for their patients. ?? Book a meeting or find more details here: https://lnkd.in/gtdjSHwr #ACC25 #YesCCT #CTFirst #DigitalHealth #Cardiology

?? Yes, Yes, Yes, and you guessed it, Yes! ?? If coronary computed tomography angiography (CCTA) isn’t part of your standard of care, it’s time to rethink your approach. CCTA provides comprehensive cardiac imaging, detecting key signs of heart disease like atherosclerosis and stenosis. It’s backed by the American College of Cardiology & American Heart Association with a Class 1, Level A recommendation—the strongest possible endorsement, supported by multiple randomized clinical trials. Combine CCTA with Cleerly, and you’ve got next-level precision! Our AI analyzes patients' CCTA images to characterize and quantify plaque to predict future cardiovascular risk. ?? See how Cleerly can transform your practice. Schedule a 1:1 demo today: https://lnkd.in/g7D-4dDa #YesCCT #CCTA #CTFirst #CardiacImaging

Small but not insignificant! ???? In the PARADIGM study, Cleerly detected small plaques (<50 mm3) on baseline CCTA, with 87% of plaques present at follow-up. Of these, 72% increased in size. Cleerly's AI-powered insights help identify and track these subtle changes, giving healthcare professionals a clearer understanding of their patients true heart health. ?? A closer look starts with Cleerly. Learn more here: https://lnkd.in/g2cXZf34 #YesCCT #CTFirst #CardiacImaging #ArterialPlaque

We think they’re pretty great, but don’t just take our word for it! ?? Join us at Booth 16033 for an exclusive meet & greet with Cleerly's leadership team at ACC.25. This is your chance to connect with the trailblazers behind Cleerly—clinical researchers, medical professionals, and innovators dedicated to raising the standard of cardiac care and improving patient outcomes with life-changing insights. ???? ?? Book your meeting today: https://lnkd.in/gtdjSHwr #ACC #ACC25 #YesCCT #CCTA #DigitalHealth

Cardiovascular disease (CVD) is still the #1 cause of death, yet today’s standard of care remains reactive, not proactive. ?? Over 50% of heart attacks occur in asymptomatic patients. ?? CVD costs are projected to hit $2 trillion by 2050. At Cleerly, we believe early detection and prevention are the key to reducing heart attacks, saving lives, and easing the burden on our healthcare system. Over a decade of research confirms the type of atherosclerotic plaque—not just risk factors—matter most. Our AI-powered advanced plaque analysis delivers precise, personalized insights, shifting cardiac care from late-stage intervention to true prevention. It's time to rethink cardiac care. Learn more here: https://lnkd.in/gfjBrhcg #YesCCT #CCTA #Cardiology #CardiacCare #DigitalHealth

Community first! ??? Before ACC.25 officially begins, we’re hitting the ground in Chicago a little early for some heart-healthy education. On March 25, we’re proud to support the American College of Cardiology at the Chicago Community Health Fair—an event dedicated to raising awareness about heart disease risk factors and educating the community with actionable strategies for improving heart health. Alongside Johnson & Johnson and Amgen, we're joining local healthcare leaders to empower Chicago with knowledge that can lead to a healthier future. Learn more here: https://lnkd.in/gwgEgEAR #ACC #ACC25 #HeartHealth #HeartDisease #Community #CardioSmart #HealthFair

?? According to the American Heart Association, nearly 45% of women aged 20 and older are living with some form of cardiovascular disease. ?? Our latest webinar offers a scientific overview of the benefits of coronary CTA and AI-powered plaque analysis in accurately assessing the risk of coronary artery disease in women. Join Dr. Fatima Rodriguez, MD, MPH, as she shares clinically supported insights on how understanding female-specific cardiovascular risk factors can enhance prevention and treatment strategies. Watch now and get the latest insights: https://lnkd.in/g_6PgGXG #YesCCT #CCT #Hearthealth #HeartDisease #DigitalHealth #MedTech #AIinHealthcare #AIQCT

It's time to move beyond risk factors and measure true heart health. ???? Cleerly’s AI-powered advanced plaque analysis characterizes and quantifies atherosclerosis—the root cause of heart disease. With comprehensive data on the type and amount of plaque present, healthcare professionals can more accurately assess a patient’s risk for coronary artery disease. ?? Learn more here: https://lnkd.in/g2cXZf34 #YesCCT #CCTA #CardiacImaging #ArterialPlaque #Cardiology #HeartDisease #Atherosclerosis

We love to celebrate our team! ???? Happy Employee Appreciation Day to every Cleerly employee! Your passion, dedication, and innovation are truly at the heart of our mission. You are the dreamers, innovators, and changemakers dedicated to raising the standard of cardiac care and improving patient outcomes. Because of you, we're empowering healthcare professionals with AI-driven, non-invasive tools to diagnose and manage heart disease with greater precision. We're honored to be on this journey together! ?? #EmployeeAppreciationDay #ThankYou #ThankYouTeam #EmployeeRecognition

If you haven't heard of AI-QCT, now's the time! A study utilizing Cleerly's AI-driven plaque analysis has been recognized as one of the Top 10 papers in Ischaemic Heart Disease by the European Heart Journal! ???? A huge shoutout to our research fellow in Amsterdam, Dr. Nick Nurmohamed, and the entire team for their dedication to advancing heart disease risk assessment. This work highlights how AI-powered CCTA (AI-QCT) analysis may enhance risk assessment, bringing us closer to a future where cardiac care is proactive, precise, and personalized. Curious to read the paper? Check it out here: https://lnkd.in/gZvbn83P #Cleerly #Cardiology #ResearchExcellence #HeartHealth #YesCCT #CCTA #ClinicalEvidence